Nanobiotix S.A. (NBTX)
- Previous Close
5.90 - Open
5.91 - Bid --
- Ask --
- Day's Range
5.91 - 5.91 - 52 Week Range
1.75 - 11.00 - Volume
385 - Avg. Volume
29,841 - Market Cap (intraday)
279.089M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-1.16 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
12.03
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.
www.nanobiotix.comRecent News: NBTX
Performance Overview: NBTX
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NBTX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NBTX
Valuation Measures
Market Cap
272.19M
Enterprise Value
245.74M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.78
Price/Book (mrq)
--
Enterprise Value/Revenue
8.18
Enterprise Value/EBITDA
-8.17
Financial Highlights
Profitability and Income Statement
Profit Margin
-109.64%
Return on Assets (ttm)
-21.78%
Return on Equity (ttm)
--
Revenue (ttm)
36.21M
Net Income Avi to Common (ttm)
-39.7M
Diluted EPS (ttm)
-1.16
Balance Sheet and Cash Flow
Total Cash (mrq)
75.28M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-9.4M